Bizarre Patents
Mouthguard made at least partially from an edible candy
A mouthguard includes a U-shaped upper bite plate which removably fits over upper teeth of a person, with the entire upper bite plate being made from a soft, deformable and edible gummi candy.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7332173 | Group A streptococcal polysaccharide immunogenic compositions and methods This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently lin... | 02/19/2008 |
| 7291343 | antigens and vaccines A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. fa... | 11/06/2007 |
| 7252828 | Polysaccharide vaccine for infections The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. Th... | 08/07/2007 |
| 7169392 | serogroup B glycoconjugates and methods of producing the same The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (Men... | 01/30/2007 |
| 7101562 | Conjugate vaccines for the prevention of dental caries The present invention provides glucan-based compositions and methods for stimulating an immune response against mutans streptococci components and vaccines and methods for the treatment and prevention of dental caries. In a preferred embodiment, a glucan polymer, pr... | 09/05/2006 |
| 7005129 | Non-toxic mutants of pathogenic gram-negative bacteria A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a m... | 02/28/2006 |
| 6984381 | Vaccine for the prevention of bacterial infection of the bovine mammary gland A novel vaccine for immunizing animals against Staphylococcus aureus-induced mastitis is disclosed. The vaccine is comprised of whole killed cells of S. aureus in a dosage effective to immunize an animal against the organism, in combination with a phar... | 01/10/2006 |
| 6855321 | Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. The... | 02/15/2005 |
| 6764686 | Modified immunogenic pneumolysin compositions as vaccines This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin va... | 07/20/2004 |
| 6638513 | Neisseria meningitidis serogroup B Glycoconjugates The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS deri... | 10/28/2003 |
| 6602508 | Method of immunization using a Group B Streptococcus type II and type III polysaccharide conjugate vaccine The process for depolymerizing Group B Types II and III streptococcal polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize ... | 08/05/2003 |
| 6596283 | Meningococcal polysaccharide conjugate vaccines The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the... | 07/22/2003 |
| 6423320 | Inhibitor of immunoglobulin E antibody production A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibit the IgE antibody production and response and, therefore, are useful in the prophylaxis and/or treatment of type I allergy-related diseases.... | 07/23/2002 |
| 6372222 | Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof The process for depolymerizing Group B Types II and III Streptococcal Polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize ... | 04/16/2002 |
| 6333036 | Vaccine composition containing polyribosylribitol phosphate and method for making same Vaccine compositions are disclosed which comprise at least one antigen formed by the capsular polysaccharide of Haemophilus influenzae type b or high molecular weight polyribosylribitol phosphate coupled to tetanus anatoxin.... | 12/25/2001 |
| 6280738 | Non-IgA Fc binding forms of the group B streptococcal ଲ antigens A-X202 X203 X204 X205 X206 X207 X208 X209 X210 X211 X212 X213 -B, wherein A represents amino acid residues 38-201 of SEQ ID NO: ... | 08/28/2001 |
| 6251401 | Combined meningitis vaccine A combined vaccine for bacterial meningitis comprises Hib and MenC oligosaccharide conjugates.... | 06/26/2001 |
| 6177085 | Generation of immune response using immunogenic conjugate of molecules Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular... | 01/23/2001 |
| 6045805 | Oligosaccharide derived from an antigenic polysaccharide obtained from a pathogenic agent An oligosaccharide derived from an antigen polysaccharide obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligosaccharide is prepared by oxidation-reduction depolymerization reaction.... | 04/04/2000 |
| 6007818 | Oligosaccharide derived from an antigenic polysaccharide obtained from a pathogenic agent An oligoside derived from an antigen polyoside obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligoside is prepared by oxidation-reduction depolymerisation reaction.... | 12/28/1999 |
| 5968548 | Use of liposome encapsulated cirprofloxacin as an immunotherapeutic drug Liposome-encapsulated quinolones and specifically liposome-encapsulated ciprofloxacin dramatically enhances macrophage functions, induces NO production and augments the production of cytokines, rendering the composition an immunoprophylactic and immunothe... | 10/19/1999 |
| 5770213 | Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use i... | 06/23/1998 |
| 5700787 | Capsular polysaccharide immunomodulator Methods and products for protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. Methods for forming immunomodulators and pharmaceutical compositions relating thereto als... | 12/23/1997 |
| 5679654 | Capsular polysaccharide immunomodulator Methods and products for protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. Methods for forming immunomodulators and pharmaceutical compositions relating thereto als... | 10/21/1997 |
| 5445817 | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines A medically important and useful conjugate comprising pertussis toxin (PT), or another antigen having similar physico-chemical properties, as the carrier protein component, coupled to a neutral or non-charged saccharide, particularly, the capsular polysac... | 08/29/1995 |
| 5371197 | Protein-dimeric polysaccharide conjugate vaccine A conjugate immunogen, having polysaccharide moieties derived from bacterial sources, provides a multivalent vaccine with a low protein to polysaccharide ratio. The vaccine reduces complications associated with injection of protein immunogens due to pyrog... | 12/06/1994 |
| 5360897 | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 11/01/1994 |
| 5334379 | Cytokine and hormone carriers for conjugate vaccines This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lym... | 08/02/1994 |
| 5314811 | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide A process for converting lipid-containing bacterial capsular polysaccharide, such as lipo-polyribosyl ribitol phosphate, lipo-PRP, into lipid-free, endotoxin-free polysaccharide, such as polyribosyl ribitol phosphate, PRP, by solubilizing polysaccharide-c... | 05/24/1994 |
| 5306492 | Oligosaccharide conjugate vaccines The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular p... | 04/26/1994 |
| 5204098 | Polysaccharide-protein conjugates Vi capsular polysaccharides conjugated to toxin-dependent proteins can be used to enhance antibody response and to convert T-dependent properties to the Vi capsular polysaccharide. A heterobifunctional crosslinking agent can be used to bind thiol derivati... | 04/20/1993 |
| 5192540 | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine Immunogenic conjugates of a 38,000 daltons or 40,000 daltons outer membrane protein of H. influenzae type b and oxidized polyribosyl-ribitol-phosphate polysaccharide fragments of H. influenzae type b are disclosed. Vaccines containing the conjugates are d... | 03/09/1993 |
| 5097020 | Immunogenic conjugates An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 03/17/1992 |
| 5071969 | Sulphated K5 antigen and sulphated K5 antigen fragments The invention relates to sulphated K5 antigen and sulphated K5 antigen fragments containing at least 3 monosaccharide units and salts thereof, having interesting antiangiogenic and antitumor activities and a favorable ratio of the activities with respect ... | 12/10/1991 |
| 5045456 | Process for removing bacterial endotoxin from gram-negative polysaccharides A process for removing endotoxin from Gram-negative polysaccharides such as H. influenzae polyribosylribitol phosphate by adding alcohol incrementally until substantially all lipopolysaccharide precipitates.... | 09/03/1991 |
| 5039610 | Process for removing bacterial endotoxin from gram-negative polysaccharides A process for removing endotoxin from Gram-negative polysaccharides such as polyribosylribitol phosphate by solubilizing polysaccharide-containing powder derived from Gram-negative bacteria fermentation broth to provide a divalent counter ion for endotoxi... | 08/13/1991 |
| 5019502 | Process for removing bacterial endotoxin from gram-negative polysaccharides A process for removing endotoxin from Gram-negative polysaccharides such as H. influenzae polyribosylribitol phosphate by mixing with a nonionic resin, a detergent and a chelating agent.... | 05/28/1991 |
| 4954449 | Human monoclonal antibody reactive with polyribosylribitol phosphate A human monoclonal antibody produced by a self-reproducing carrier cell, antibody being reactive with PRP capsular polysaccharide. Also disclosed is a process of preparing the antibody from the carrier cell, which is conveniently a hybridoma. Additional... | 09/04/1990 |
| 4902506 | Immunogenic conjugates An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 02/20/1990 |
| 4830852 | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins and methods of preparing such polysaccharides and conjugates Covalently-modified neutral bacterial polysaccharides; covalent conjugates of such polysaccharides linked by a bigeneric spacer, with immunogenic bacterial membrane or other proteins, which conjugates are useful components of bacterial vaccines; and metho... | 05/16/1989 |
